<?xml version="1.0" encoding="UTF-8"?>
<p>Each viral polymerase is an attractive target for developing a new antiviral compound. The inhibitors should work against several subtypes of influenza A viruses and be tolerated by a drug-resistant mutant because it is highly conserved in all influenza subtypes and is essential to the viral life cycle. We have previously reported on a highly potent antihuman immunodeficiency virus (HIV) nucleoside derivative called 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA, 
 <bold>1</bold>, 
 <xref ref-type="fig" rid="molecules-24-02603-f001">Figure 1</xref>) [
 <xref rid="B5-molecules-24-02603" ref-type="bibr">5</xref>,
 <xref rid="B6-molecules-24-02603" ref-type="bibr">6</xref>,
 <xref rid="B7-molecules-24-02603" ref-type="bibr">7</xref>,
 <xref rid="B8-molecules-24-02603" ref-type="bibr">8</xref>,
 <xref rid="B9-molecules-24-02603" ref-type="bibr">9</xref>,
 <xref rid="B10-molecules-24-02603" ref-type="bibr">10</xref>,
 <xref rid="B11-molecules-24-02603" ref-type="bibr">11</xref>,
 <xref rid="B12-molecules-24-02603" ref-type="bibr">12</xref>,
 <xref rid="B13-molecules-24-02603" ref-type="bibr">13</xref>]. EFdA is an adenosine derivative armed with an ethynyl group at the 4′-position, which prevents the extension of a nucleotide at 3′-OH because of its steric hindrance by the 4′-substituent, providing features of a viral DNA chain terminator and a reverse transcriptase inhibitor [
 <xref rid="B14-molecules-24-02603" ref-type="bibr">14</xref>,
 <xref rid="B15-molecules-24-02603" ref-type="bibr">15</xref>,
 <xref rid="B16-molecules-24-02603" ref-type="bibr">16</xref>,
 <xref rid="B17-molecules-24-02603" ref-type="bibr">17</xref>,
 <xref rid="B18-molecules-24-02603" ref-type="bibr">18</xref>]. EFdA is currently used in human clinical trials [
 <xref rid="B19-molecules-24-02603" ref-type="bibr">19</xref>,
 <xref rid="B20-molecules-24-02603" ref-type="bibr">20</xref>,
 <xref rid="B21-molecules-24-02603" ref-type="bibr">21</xref>,
 <xref rid="B22-molecules-24-02603" ref-type="bibr">22</xref>,
 <xref rid="B23-molecules-24-02603" ref-type="bibr">23</xref>,
 <xref rid="B24-molecules-24-02603" ref-type="bibr">24</xref>]. Herein, we hypothesize that EFdA derivatives may work as an anti-influenza inhibitor. We subsequently describe the discovery of a new 4′-ethynyl-2′-deoxyadenosine 5′-monophosphate analog called EdAP (
 <bold>5</bold>) as a potent inhibitor of influenza A virus. Interestingly, this DNA-type nucleic acid analog inhibited the multiplication of influenza A virus, although influenza A virus is an RNA virus that does not generate DNA.
</p>
